Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

January 14th 2021

Emerging Therapies May Offer Fresh Options for TP53-Mutated MDS

January 13th 2021

Two novel treatments options may shake up the landscape for treating patients with myelodysplasia syndrome.

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

January 13th 2021

Prognostic Factors Which Impact ALL Management

January 13th 2021

Dr. DeAngelo on the Utility of Moxetumomab Pasudotox in HCL

January 13th 2021

Daniel J. DeAngelo, MD, PhD, discusses the utility of moxetumomab pasudotox-tdfk in hairy cell leukemia.

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

January 11th 2021

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Frontline CLL Treatment: Addressing Unmet Needs

January 8th 2021

Allogeneic Transplantation for CLL

January 8th 2021

Relapsed/Refractory CLL: Repeat Molecular Testing

January 8th 2021

Therapeutic Sequencing in Relapsed/Refractory CLL

January 8th 2021

CLL Patient Management During COVID-19 and Telehealth

January 8th 2021

CLL Treatment Approaches During COVID-19

January 8th 2021

Frontline CLL: Treatment Algorithms

January 8th 2021

Minimal Residual Disease in CLL

January 8th 2021

Frontline CLL Treatment With Fixed-Duration Regimens

January 8th 2021

Anti-BCL2/CD20 Combination Therapy for Frontline CLL

January 8th 2021

Anti-CD20/BTKi Therapy for Frontline CLL

January 8th 2021